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Neurofibromatosis 1 (NF1) is characterized by cutaneous, neurological and osseous 
manifestations. Most NF1 patients develop cutaneous neurofibromas. However, 
time-dependent change with aging and the predilection site of cutaneous neurofibromas 
remain unclear. To clarify the natural course and characteristics of cutaneous 
neurofibromas, a retrospective study was conducted for 57 NF1 patients who were 
treated at the Department of Dermatology of Tottori University Hospital between 
January 2007 and April 2016. For each patient, we investigated the time-dependent 
changes and the numbers of cutaneous neurofibromas in four body surface regions. 
There was a positive correlation between age and number of cutaneous neurofibromas (r 
= 0.75, p < 0.001). Cutaneous neurofibromas were located on the trunk (60.2%), lower 
limbs (16.1%), upper limbs (14.4%), and head and neck (9.2%). There was no 
significant relationship between each body type (e.g., obese or thin) and cutaneous 
neurofibromas. With respect to the year-to-year percentage change in cutaneous 
neurofibromas, the average annual rate of increase was 0.21 (range, −0.71-1.2). The 
number of cutaneous neurofibromas had increased in about 61% of the patients one year 
later. Our data will enable physicians to estimate the overall state of cutaneous 
neurofibromas in NF1 and will be useful for handling cutaneous manifestations before 
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they become a serious condition. 
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Neurofibromatosis 1 (NF1) is an autosomal dominant genetic disease characterized by 
café-au-lait spots, neurofibromas, freckling, optic gliomas, Lisch nodules and bone 
deformity.1-3 Cutaneous neurofibromas are soft, dome-shaped and flesh-colored nodules. 
2-4 NF1 patients with cutaneous neurofibromas have serious cosmetic and social 
problems.5,6 Generally, the number of cutaneous neurofibromas increases with aging.7 
However, natural course and characteristics of cutaneous neurofibromas remain unclear. 
The purpose of this study was to clarify the time-dependent changes and the 
predilection site of cutaneous neurofibromas in NF1. 
 
Patients and methods 
Study population (Patients) 
A retrospective study was conducted. We investigated 57 NF1 patients (25 men and 32 
women [no pregnancy]; median age, 34 years; age range, 0-79 years) at the 
Dermatology Department of Tottori University Hospital over a 9-year period from 
January 2007 to April 2016.  
All of the patients were evaluated by expert dermatologists and met the diagnosis 
criteria by National Institutes of Health in 1988.1,8 Mosaic NF1 (localized NF1) 9,10 was 
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excluded in our study. The study protocol was approved by the Ethics Committee of 
Tottori University Hospital (No. 2671). Demographic and clinical information on age, 
sex, number of cutaneous neurofibromas and any diagnosed complications was obtained 
from medical records. For each patient, we counted the number of cutaneous 
neurofibromas (> 5mm in diameter) except for subcutaneous neurofibromas by visual 
judgement at the 4 divisions of body surface area: head and neck, trunk, upper limbs 
and lower limbs during a physical examination. In addition, we calculated ratios of the 
number of cutaneous neurofibromas per body surface area. We also investigated the 
time-dependent change in cutaneous neurofibromas after 1 year. 
 
Genetic analysis 
After obtaining informed consent, we performed genetic analysis in 20 NF1 patients by 
next-generation sequencing as previously described.11 Simply, genomic DNA was 
extracted from peripheral blood according to standard procedures. In-solution 
hybridization-based enrichment was performed using the SureSelect Target Enrichment 
system (Agilent Technologies, Santa Clara, CA, USA). When the next-generation 
sequencing protocol revealed truncating mutations, the variants were validated by direct 
capillary sequencing. The exon deletions were screened using a multiple 
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Spearman rank correlation was used to determine the correlation between number of 
cutaneous neurofibromas and age. P-values < 0.05 were considered statistically 
significant. A correlation coefficient (r) of more than 0.7 was considered to indicate 
strong correlation and 0.5 < r ≤0.7 was considered to indicate moderate correlation. All 
statistical analyses were conducted using EZR (Saitama Medical Center, Jichi Medical 
University, Saitama, Japan), which is a graphical user interface for R (The R Foundation 
for Statistical Computing, Vienna, Austria, version 2.13.0). More precisely, it is a 
modified version of R commander (version 1.32) designed to add statistical functions 
frequently used in biostatistics.12 
 
Results 
Relationship between age and number of cutaneous neurofibromas 
We evaluated the numbers of cutaneous neurofibromas in 57 NF1 patients (25 men and 
32 women [no pregnancy]; median age, 34 years). Demographic and clinical 
8 
 
information is shown in TableⅠ.The number of cutaneous neurofibromas increased 
after puberty. The average number of cutaneous neurofibromas in patients with a family 
history was larger than that in patients without a family history (p < 0.0113). There was 
no difference in the number of cutaneous neurofibromas between men and women (not 
shown). 
A representative case is shown in Fig. 1. There were 226 cutaneous neurofibromas on 
the trunk. There was a strong positive correlation between age and number of cutaneous 
neurofibromas (r = 0.75, p < 0.001) (Fig. 2). The number of neurofibromas increased 
with aging. 
 
Predilection site of cutaneous neurofibromas 
Since there are few cutaneous neurofibromas before puberty (as shown in TableⅠ), 
patients under 20 years old were excluded. 
Forty-one of the 57 patients (17 men and 24 women [no pregnancy]; median age, 40 
years, age range, 21-79 years) could be evaluated because there were records of the 
number of neurofibromas at each site. In the cases evaluated, 60.2% of the cutaneous 
neurofibromas were on the trunk, 16.1% were on the lower limbs, 14.4% were on the 
upper limbs and 9.2% were on the head and neck (Fig. 3a). The number was large on 
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the trunk and was small on the lower limbs. 
We also evaluated the ratio of the number of cutaneous neurofibromas per body surface 
area. The Lund and Browder Chart is commonly used for measuring the percentage of 
total body-surface area (TBSA, %).13 According to the Lund and Browder Chart, the 
ratios of neurofibromas based on the total body-surface area were 1.9 on the trunk, 1.0 
on the head and neck, 0.8 on both upper limbs and 0.4 on both lower limbs (Fig. 3b). 
Thus, the ratio was also high on the trunk and was low on the limb. 
In addition, we investigated the number of cutaneous neurofibromas in association with 
body constitutional differences (e.g., obese or thin) in each patient by using DuBois 
formula. There was no significant difference between each body type and number of 
cutaneous neurofibromas (r = -0.23, p = 0.181) (Fig. 4). The number of cutaneous 
neurofibromas was not related to body constitution.  
 
Time course change in number of cutaneous neurofibromas  
In order to determine the time course change in neurofibromas, we investigated the 
number of neurofibromas in 36 NF1 patients (14 men and 22 women; median age, 36 
years; age range, 4-79 years) 1 year later. 
The year-to-year percentage change in the number of cutaneous neurofibromas is shown 
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in Fig. 5. The number of cutaneous neurofibromas had increased in about 61% of the 
patients one year later. The average annual rate of increase was 0.21 (range, −0.71-1.2). 
There was a linear association between patients and year-to-year percentage change in 
the number of cutaneous neurofibromas.  
 
Relationship between type of NF1 mutation and cutaneous neurofibromas 
NF1 mutation was detected in 16 of 20 patients (7 (35%) frameshift, 6 (30%) missense, 
3 (15%) deletion and 4 (20%) negative). There was no significant difference between 
each type of NF1 mutation and number of cutaneous neurofibromas (not shown).  
However, numerous cutaneous neurofibromas (≧4500) were recognized in a patient 
with whole NF1 deletion. 
 
DISCUSSION 
NF1 has cutaneous, neurological and osseous complications.1,2,14 One of the major 
features of NF1 is cutaneous neurofibromas.2,3,14 Huson et al. indicated that cutaneous 
neurofibromas increased with aging.7 However, to our knowledge, there has been no 
statistical analysis of an association between cutaneous neurofibromas and age. 
Therefore, we investigated the natural course of cutaneous neurofibromas. In our study, 
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we revealed for the first time positive correlation between cutaneous neurofibromas and 
age statistically.  
We also investigated the differences in the number of cutaneous neurofibromas in 
relation to family history. There was a significant relationship between family history 
and number of cutaneous neurofibromas (TableⅠ) (p < 0.05). Clinical symptoms in 
patients with a family history of NF1 seem to be more serious than those in patients 
without a family history of NF1.  
Palmer et al. investigated associations between the presence of diffuse plexiform 
neurofibromas, cutaneous neurofibromas, and café-au-lait spots in individual body 
segments of NF1 patients.15 They concluded that there was no significant correlation 
among them. Kaufmann et al. reported that the number of visible cutaneous 
neurofibromas was larger in a high temperature area (trunk) than in low temperature 
areas (arms/legs).16 They compared the distributions of cutaneous neurofibromas by 
thermographs. However. it was difficult to assess the relation by their methods precisely 
because cutaneous neurofibromas have abundant blood supply themselves. In our study, 
we made it clear that the ratio of cutaneous neurofibromas was high on the trunk and 
was low on the limbs significantly. 
It is well known that mast cells and Schwann cells play an important role in the 
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pathogenesis of cutaneous neurofibromas in NF1.17 Therefore, the difference in 
distributions of mast cells or Schwann cells at each body site may be associated with the 
frequency of cutaneous neurofibromas. Weber et al. reported that the mast cell 
population was large at peripheral skin sites (hands and feet).18 We previously studied 
the number of mast cells on cutaneous neurofibromas at various body sites. In that study, 
the number of mast cells was not related to the number of cutaneous neurofibromas.19 
This means that the distribution of mast cells is not related to the large number of 
cutaneous neurofibromas on the trunk. On the other hand, there has been no report on 
the distribution of Schwann cells in human skin. The relationship between Schwann 
cells and number of cutaneous neurofibromas is not clear because it is difficult to 
evaluate the accurate distribution of Schwann cells in peripheral nerves. The distribution 
of peripheral nerves might be one of the reasons why there is a definite difference in the 
number of neurofibromas among body areas. 
In daily medical examinations, NF1 patients are reluctant to show their whole body. 
Physicians can observe only lesions located on the head and neck or the limbs. 
Therefore, it is often difficult to estimate the overall state of cutaneous neurofibromas in 
patients with NF1. Once numerous cutaneous neurofibromas develop, much effort is 
needed to improve impaired quality of life for NF1 patients due to cutaneous 
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manifestations. In this study, we revealed natural course and characteristics of cutaneous 
neurofibromas. Based on our findings, physicians can estimate the total number of 
cutaneous neurofibromas on the whole body and predict the state of cutaneous 
neurofibromas, which is helpful to prevent serious cosmetic condition by the 
development of cutaneous neurofibromas. We believe that our findings will be useful 
for treatment of patients with NF1. In this study, we investigated the number of 
cutaneous neurofibromas by visual judgement. However it might be a time-consuming 
task for physicians. In order to save the time and effort for counting, we are trying to 
develop image analysis system to estimate the number of cutaneous neurofibromas in 
the future.  
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Figure 1) A representative case of NF1 in a 39-year-old patient. There were 226 
cutaneous neurofibromas on the trunk.  
Figure 2) Relationship between age and number of neurofibromas (r = 0.75, p < 0.001).  
Figure 3) (a) Predilection site of cutaneous neurofibromas. (b) The ratios of 
neurofibromas based on the total body-surface area.  
Figure 4) Between each body type used by the DuBois formula and number of 
cutaneous neurofibromas (r = -0.23, p = 0.181).  
Figure 5) Year-to-year percentage change in the number of cutaneous neurofibromas.  
 
 
 
 
 
 







